DOCSLIB.ORG

GRAS Notice 666, Chondroitin Sodium Sulfate

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

ORIGINAL SUBMISSION AM IN T ALATI & UPADHYE ATTO R NEYS AT LAW GRN oootot,6 As hish R. Talati 312.327.3381 Tel Ashish@A minTalati. com 312.884 .735 2 Fax A ugust 16, 20 I 6 Office of Food Add iti ve Safe ty (H FS-200) Cente r fo r Food a fety and Applied utrition Food A nd Drug Adm in istration 500 1 Campus Drive College Park, MD 20740-3835 Rc: Gener ally Rec~ed As Safe ("GRAS") Notification for Chondroitin Sodium Sulfa te Dear S ir/Madam : Pursuant to proposed 2 I CFR 170 .36, o ur clie nt, Gnosis S .p.A. (" Gnosis"), thro ugh Amin Talati & Upadhye, LLC as its attorneys, here by provides notice ofa claim that the food ingredi ent cho ndroitin sulfate sodium, described in the enclosed notification document, is exempt from the premarket approval requirement of the Federal Food, D ru g, and Cosme tic Act because it has been determined to be Generally Recognized As Safe (GRAS), based on scientific proced ures. As required, pl ease find encl osed three co pi es ofthe notification. Please do not hesitate to contact me at Ashish@ A minTalati.com or 312-327-338 1 if you have any questions or require addi tional info rmation. S incerely, (b) (6) ~~CG~D '¥~[Q) AUG 1 7 2016 OFFICE OF FOOD ADDITIVE SAFETY Amin Talat i & Upadhye, LLC • 100 South Wacker D rive, Su ite 2000 • Chicago, IL 60606 · Office (3 12) 466- 1033 • Fax (3 12) 884- 7352 • www.AminTalati.com GRAS NOTIFICATION I. Claim of GRAS Status A. Claim of Exemption from the Requirement for Premarket Approval Requirements Pursuant to Proposed 21 CFR § 170.36(c)(l) Gnosis S.p.A., Italy has determined that chondroitin sulfate sodium is Generally Recognized As Safe, consistent with Section 20l(s) of the Federal Food, Drug, and Cosmetic Act. This determination is based on scientific procedures as described in the following sections, under the conditions of its intended use as a food ingredient. Therefore, the use of chondroitin sulfate sodium is exempt from the requirement of premarket approval. Signed, (b) (6) Ashish Talati, J.D., M.S ., RAC Attorney for: Gnosis S.p.A. Via Lavoratori Autobianchi, 1 20832 Desio (MB), Italy Page I of8 r--------~~~~-- ------- -~ B. Narne and Address of N otifier: Marco Bema Gnosis S.p.A. Via Lavoratori Autobianchi 1 20832 Desio (MB) ITLY C. Common or Usual Name of the Notified Substance: The common name ofthe substance ofthis notification is chondroitin sulfate sodium. D. Conditions of Intended Use in Food Chondroitin sulfate sodium is intended for use as a nutrient [21 CFR 170.3(o)(20)] 1 in conventional foods such as beverage and beverage bases, milk and milk products, and chewing gum at use levels ranging from 50 to 200 mg/serving (reference amounts customarily consumed, 21 CFR 101.12). Chondroitin sulfate sodium is not proposed for uses in foods that are intended for infants and toddlers, such as infant formulas or foods formulated for babies or toddlers, as well as it is not intended for use in meat and poultry products that come under USDA jurisdictions. The intended use of chondroitin sulfate sodium in the above mentioned food categories, is estimated to result in a maximum daily intake of 1200 mg /person [20 mg/kg body weight (bw)/day for an individual weighing 60 kg]. E. Basis for GRAS Determination: In accordance with 21 CFR 170.30, the intended use of chondroitin sulfate sodium has been determined to be Generally Recognized As Safe (GRAS) based on scientific procedures. The determination is supported by the opinion of the Expert Panel. A comprehensive search of the scientific literature through July 2016 was also utilized for this determination. There exists sufficient qualitative and quantitative scientific evidence, including animal and human data to determine safety-in-use for chondroitin sulfate sodium. Chondroitin sulfate as a component of connective tissue is found in human body and is commonly consumed as a dietary supplement. The safety determination of chondroitin sulfate sodium is based on the totality of available evidence. The safety of chondroitin sulfate sodium is supported by multiple well designed human clinical trials and animal studies with chondroitin sulfate. In the published literature, several double-blind, placebo-controlled trials were found. In these studies, the use levels of chondroitin sulfate ranged from 800 to 1200 mg/day for long duration. Additionally, several animal and in vitro studies further corroborate the safety in use of chondroitin sulfate sodium at the intended use levels. The findings from a series of specifically designed subchronic toxicity and mutagenicity studies that followed standard regulatory guidelines, supports the safety in use of chondroitin sulfate sodium, subject of present GRAS. Based on the subchronic study, the no-observed-adverse-effect level (NOAEL) for chondroitin sulfate sodium was determined to be 1000 mg/kg bw/day, the highest dose tested. On the basis of '"Nutrient supplements": Substances which are necessary for the body's nutritional and metabolic processes. Page 2 of8 - -----------------------------, scientific procedures 2 , Gnosis S.p.A. considers the consumption of chondroitin sulfate sodium, as a food ingredient to be safe at levels up to 1200 mg/person/day. F. Availability of Information: The data and information that forms the basis for this GRAS determination will be provided to Food and Drug Administration upon request or will be available for FDA review and copying at reasonable times at the above mentioned offices of the notifier (Section I, B) or at the offices of: Madhu G. Soni, PhD, FATS Soni & Associates Inc 749 46th Square Vero Beach, FL 32068 Telephone:+ 1- 772-299-0746 Email: [email protected] II. Detailed Information About the Identity of the Notified Substance: Chondroitin sulfate sodium is a standardized amorphous white to off-white powder produced by fermentation of a particular strain of E. coli to produce the K4 polysaccharide that is further chemically transformed to chondroitin sulfate sodium. The product is chemically pure. A. Chemical name: Chondroitin sulfate is a glycosaminoglycan, a linear polymer constituted of random sequences ofrepeated disaccharide units of: 2-acetylamino-2-deoxy-4-0-sulfate- 3 -0-~-D-glucopyranurosyl-D-galactose 2-acetylamino-2-deoxy-6-0-sulfate- 3 -0-~-D-glucopyranurosyl-D-galactose 2-acetylamino-2-deoxy-4,6-0-disulfate-3-0-~-D-glucopyranurosyl-D-galactose 2-acetylamino- 2-deoxy-6-0-sulfate-3 -0-~-2'-0-sulfate-D-glucopyranurosyl-D-galactose B. Chemical Abstract Registry and other Number: Chondroitin Sulfate Sodium Salt: [CAS: 9082-07-9] Chondroitin sulfate C: [12678-07-8], [25322-46-7] Chondroitin sulfate mixture of regioisomers A, C, E: [9007 -28-7] C. Chemical Formula and Molecular Weight: Monosulfated disaccharide unit: Cr4Hr9NNa20 14S (molecular weight= 503.3) Bisulfated disaccharide unit: Cr4H2oNNa3017S2 (molecular weight= 605.4) Monosulfated polymer: (Cr4Hr9NNa2014S)nH20; n> 1 [molecular weight= (503.3)n+18] Bisulfated polymer: (C 14H2oNNa30r 7Si)nH20; n> 1 [molecular weight = (605 .4)n+ 18] 2 21 CFR §170.3 Defmitions. (h) Scientific procedures include those human, animal, analytical, and other scientific studies, whether published or unpublished, appropriate to establish the safety of a substance. Page 3 of8 D. Structure: The structural formula of chondroitin sulfate is presented in Figure II-D. _...[4)-p-0-GicA-( I + 3)-p-0-GaiNAc(1_.Jn Chondroitin Sulfate Chemical Formula : (C1. H 19NNa20 14S)n H20 Molecular Weight: (503,34)n + 18 R4,R6=H or S03Na Ft. different from R6 Figure 11-D. Chemica l Structure of Chondroitin Sulfate Sodium E. Physical Characteristics Chondroitin sulfate sodium is an amorphous white to off-white powder. F. Identity and Specifications Food grade specifications of chondroitin sulfate sodium are presented in Tables II-G.l. The product is highly pure and contains >95% chondroitin sulfate sodium. The identity of chondroitin sulfate sodium is confirmed by employing N uclear Magnetic Resonance (NMR) spectra. Chondroitin sulfate sodium is the only main ingredient present in the product. Analytical data from three nonconsecutive manufacturing lots are presented in Appendix I. Page 4 of8 Table ll-F. Specifi ca tio ns of C ho ndroitin Sulfate Sodium ( MythocondroTM) Tests Limits Limits Ref. Analytical M ethods Ref. Appearance White to lo-house USP monograph off-white powder Identification : USP monograph USP monograph -IR Positive -Sodium Positive Clarity and Color ofsolution ~ 0.35 USP monograph USP monograph (5% aqueous solution, abso rbance at 420 nrn) Specifi c Optical Rotation -7.0° to - 19.0° d.b. In-house USP monograph (3% aqueous solution) pH ( 1% aqueous solution) 5.5 to 7.5 USP monogr!iJ>h USP monograph Loss on drying ~ 10.0 % USP monog raph USP monograph (105 °C for 4 hours) Residue on ign ition 20.0% to 30.0 % d.b. USP monograph USP monograph Chloride < 0.50 % USP monograph USP mon ograp h Sulfate < 0 .24 % USP monograph USP monograph Heavy metals < 0.002 % USP monograph USP monograph Lead ~ 0.5 ppm USP <23 3> USP <233 > Cadmium < 0 .5 ppm USP <23 3> USP <233> Mercury < 0 . 1 ppm US P <233> USP <233> Arsenic < 1.5 ppm US P <233> USP <233 > Electrophoretic purity: US P monograp h USP monograph -any ind ividual impurity < 2% Microbial enumeration: USP monograph USP monog raph - Tota l bacterial count S 103 CFU/g -Total combined yeasts and molds S 102 CFU/g - Salmone lla s p. Absent I 10 g -Escherichia coli Absent/tO g Limit of prote in < 0 .5% d.b. In-house USP monograph Content of chondroitin s ul fate 95 .0 % to 105.0% d.b. In-house USP monograph sod ium G.
Recommended publications
  • Associations of Regular Glucosamine Use with All-Cause and Cause

    Associations of Regular Glucosamine Use with All-Cause and Cause

    Epidemiology Ann Rheum Dis: first published as 10.1136/annrheumdis-2020-217176 on 6 April 2020. Downloaded from EPIDEMIOLOGICAL SCIENCE Associations of regular glucosamine use with all- cause and cause- specific mortality: a large prospective cohort study Zhi- Hao Li,1 Xiang Gao,2 Vincent CH Chung,3 Wen- Fang Zhong,1 Qi Fu,3 Yue- Bin Lv,4 Zheng- He Wang,1 Dong Shen,1 Xi- Ru Zhang,1 Pei-­Dong Zhang,1 Fu- Rong Li,1 Qing- Mei Huang,1 Qing Chen,1 Wei- Qi Song,1 Xian- Bo Wu,1 Xiao-­Ming Shi,4 Virginia Byers Kraus,5 Xingfen Yang,6 Chen Mao 1 Handling editor Josef S ABSTRact Key messages Smolen Objectives To evaluate the associations of regular glucosamine use with all-cause and cause-specific ► Additional material is What is already known about this subject? published online only. To view mortality in a large prospective cohort. ► Although several epidemiological investigations please visit the journal online Methods This population- based prospective cohort indicated that glucosamine use might play a (http:// dx. doi. org/ 10. 1136/ study included 495 077 women and men (mean (SD) role in prevention of cancer, cardiovascular annrheumdis- 2020- 217176). age, 56.6 (8.1) years) from the UK Biobank study. disease (CVD), and other diseases, only a Participants were recruited from 2006 to 2010 and For numbered affiliations see few studies have evaluated the associations were followed up through 2018. We evaluated all-cause end of article. between glucosamine use and mortality mortality and mortality due to cardiovascular disease outcomes, especially for cause- specific Correspondence to (CVD), cancer, respiratory and digestive disease.
  • Orthopaedic Bioengineering Research Laboratory 2010-2011

    Orthopaedic Bioengineering Research Laboratory 2010-2011

    2010-2011 Report including the Orthopaedic Bioengineering Research Laboratory Preface It is my pleasure to present our 2010-2011 report been possible without a number of our donors from the Orthopaedic Research Center and the stepping up to provide supplemental funding. Orthopaedic Bioengineering Research Laboratory I’m particularly grateful to Mr. Jim Kennedy for at Colorado State University. Our principal focus providing supplemental operating funds and continues to be solving the significant problems in continuing the legacy of his mother, Barbara Cox equine musculoskeletal disease as can be seen in this Anthony. I’m also grateful to Abigail Kawananakoa report but we also continue to investigate questions for continued support over and above the Endowed relevant to human joint disease and techniques Chair she donated three years ago; and Herbert Allen and devices for human osteoarthritis and articular for continuing to provide considerable support for cartilage repair when the technique can also benefit investigation of cutting edge therapies. the horse. There have been a number of notable projects in this regard. The studies, led by Dr. Dave We have added an Equine Sports Medicine Frisbie at the ORC in partnership with Dr. Alan Ambulatory clinical arm to the Orthopaedic Research Grodzinsky at MIT on an NIH Program Grant in Center and also initiated two residencies in Sports cartilage repair, have been completed and results Medicine and Rehabilitation. This follows on from are still be analyzed. We have three other ongoing the accreditation of a new specialty college, the NIH grants in partnership with collaborators. One is American College of Veterinary Sports Medicine and with Dr.
  • Osteoarthritis (OA) Is a Pain

    Osteoarthritis (OA) Is a Pain

    R OBE 201 CT 1 O Managing Osteoarthritis With Nutritional Supplements Containing Glucosamine, Chondroitin Sulfate, and Avocado/Soybean Unsaponifiables steoarthritis (OA) is a pain- successfully recommending OJHSs treatment algorithm exists for man- ful, progressive degeneration containing a combination of glu- aging patients with OA, acetamin- O of the joint characterized by cosamine, chondroitin sulfate (CS), ophen is a first-line drug recom- progressive cartilage loss, subchon- and avocado/soybean unsaponifi- mended to help control pain and dral bone remodeling, formation of ables (ASU) for the management increase mobility. Acetaminophen periarticular osteophytes, and mild of OA. It will briefly review the is associated with both hepatic and to moderate synovitis accompanied available pharmacokinetics/phar- renal damage, particularly in patients by an increase in pro-inflammatory macodynamics and safety profile who exceed the recommended daily cytokines, chemokines, and a vari- of OJHSs containing a mixture of dose or use it in combination with ety of inflammatory mediators.1 glucosamine, CS, and ASU, outline moderate amounts of alcohol. 6 There is no cure for OA; therefore, strategies to identify appropriate Worsening pain, disease progression, once an individual is diagnosed, patients for OJHSs containing these and inefficacy of acetaminophen managing OA becomes a lifelong ingredients, and provide web-based often necessitate initiating prescrip- process. Although a physician ini- resources (TABLE 1) that will assist tion NSAIDs (such as COX-2 tially diagnoses OA, pharmacists are pharmacists in educating and coun- inhibitors), which carry the risk of the most accessible health care pro- seling patients. gastrointestinal effects (e.g., gas- fessional and play an integral role tropathy), renal toxicities, and seri- in managing each patient’s joint CURRENT RECOMMENDATIONS ous cardiovascular events.
  • Identification of Glucosamine Hydrochloride Diclofenac Sodium Interaction Products by Chromatography-Mass Spectrometry

    Identification of Glucosamine Hydrochloride Diclofenac Sodium Interaction Products by Chromatography-Mass Spectrometry

    Available online www.jocpr.com Journal of Chemical and Pharmaceutical Research, 2014, 6(5):761-767 ISSN : 0975-7384 Research Article CODEN(USA) : JCPRC5 Identification of glucosamine hydrochloride diclofenac sodium interaction products by chromatography-mass spectrometry А. А. Sichkar Industrial Pharmacy Department, National University of Pharmacy, Kharkiv, Ukraine _____________________________________________________________________________________________ ABSTRACT Researches of chemical transformation products of diclofenac sodium and glucosamine hydrochloride at their joint presence have been carried out by means of the gas chromatography-mass spectrometry. Mechanical mixes of substances were investigated before and after technological operations of humidifying and drying. It has been proven that one medicinal substance influences another. The formation of several reaction products during the chemical interaction between diclofenac sodium and glucosamine hydrochloride has been shown. Key words: diclofenac sodium, glucosamine hydrochloride, chemical transformation products, gas chromatography-mass spectrometry. _____________________________________________________________________________________________ INTRODUCTION Diclofenac sodium is in the first line of nonsteroidal anti-inflammatory drugs (NSAID) for the pain relief and reduction of an inflammatory process activity in most diseases of connective tissue and joints over decades. However, along with pronounced therapeutic effect the use of this NSAID is associated with several side effects, including lesions of the gastrointestinal tract and inhibition of the metabolism of articular cartilage [1, 2, 3, 4]. Creation of new combined drugs with NSAIDs and other medicinal substances is one of the major direction of NSAIDs pharmacological properties spectrum spread and reduce their toxicity [5, 6, 7, 8]. Thus, in the National University of Pharmacy at the Department of Clinical Pharmacology and Clinical Pharmacy under the supervision of prof. Zupanets I.A.
  • ACPA Guide to Pain Management

    ACPA Guide to Pain Management

    [Document title] [Document subtitle] Abstract [Draw your reader in with an engaging abstract. It is typically a short summary of the document. When you’re ready to add your content, just click here and start typing.] ACPA [Email address] 1 ACPA Resource Guide To Chronic Pain Management An Integrated Guide to Medical, Interventional, Behavioral, Pharmacologic and Rehabilitation Therapies 2019 Edition American Chronic Pain Association P.O. Box 850 Rocklin, CA 95677 Tel 800-533-3231 Fax 916-652-8190 E-mail [email protected] Web Site http://www.theacpa.org Copyright 2019 American Chronic Pain Association, Inc. All rights reserved. No portion of this book may be reproduced without permission of the American Chronic Pain Association, Inc. 2 Table of Contents A STATEMENT FROM THE ACPA BOARD OF DIRECTORS ...........................................................................................................................5 INTRODUCTION ........................................................................................................................................................................................................6 OVERVIEW OF CHRONIC PAIN TREATMENT ..................................................................................................................................................8 WHAT DOES SUCCESSFUL PAIN TREATMENT LOOK LIKE? .......................................................................................................................8 PAIN TYPES, SOURCES & CLASSIFICATION .....................................................................................................................................................9
  • Treatment on Gouty Arthritis Animal Model

    Treatment on Gouty Arthritis Animal Model

    Journal of Applied Pharmaceutical Science Vol. 7 (07), pp. 202-207, July, 2017 Available online at http://www.japsonline.com DOI: 10.7324/JAPS.2017.70729 ISSN 2231-3354 Anti-inflammatory and anti-hyperuricemia properties of chicken feet cartilage: treatment on gouty arthritis animal model Tri Dewanti Widyaningsih*, Widya Dwi Rukmi Putri, Erni Sofia Murtini, Nia Rochmawati, Debora Nangin Department of Agricultural Product Technology, Faculty of Agricultural Technology, Brawijaya University, Malang 65145, Indonesia. ABSTRACT ARTICLE INFO Article history: Gout is a form of inflammatory arthritis caused by the deposition of uric acid. The therapeutic approach to gout Received on: 22/03/2017 is mainly divided by the treatment of inflammation and the management of serum urate level. This study aim to Accepted on: 13/05/2017 investigate whether chondroitin sulfate (CS) and glucosamine in chicken feet cartilage powder (CFE) and Available online: 30/07/2017 aqueous extract (AE) are able to decrease serum urate level and inflammation in animal model of gouty arthritis. CFE and AE were evaluated in vitro for xanthine oxidase (XO) inhibition. The anti-hyperuricemic activity and Key words: liver XO inhibition were evaluated in vivo on oxonate-induced hyperuricemia rats. Anti-inflammatory property Chicken feet cartilage, gout, was also determined on monosodium urate (MSU) crystal-induced paw edema model. CFE and AE hyperuricemia, monosodium supplementation showed urate-lowering activity. However, both treatments were not able to inhibit in vitro and urate, inflammation. in vivo XO activity. In MSU crystal-induced mice, the levels of paw swelling and lipid peroxidation were increased; in addition, a decrease in the activities of SOD and changes in the expression of CD11b+TNF-α and CD11b+IL-6 of the spleen were demonstrated.
  • Compound Isolated from the Cock's Comb and Its Effect on Palmar Arsenical Keratosis

    Compound Isolated from the Cock's Comb and Its Effect on Palmar Arsenical Keratosis

    | Clinical | Trial | Compound isolated from the cock’s comb and its effect on palmar arsenical keratosis Hazera Sharmin and Mir Misbahuddin Article Info Abstract Division of Arsenic Research, This study was conducted to confirm the effectiveness of the ointment containing cock’s comb Department of Pharmacology, Faculty of extract and to identify the compound that was effective in the treatment of palmar arsenical Basic Science and Paraclinical Science, Bangabandhu Sheikh Mujib Medical keratosis. On the basis of inclusion and exclusion criteria, 24 patients with moderate to severe University, Shahbag, Dhaka, Bangladesh palmar arsenical keratosis were enrolled from an arsenic endemic area. The ointment prepared from the cock’s comb extract was supplied to each patient at an interval of 2 weeks. Each patient For Correspondence: was advised to apply the ointment on the nodule by rubbing gently up to 5 minutes and twice Mir Misbahuddin daily for 12 weeks. Improvement was monitored by measuring the nodular size before starting [email protected] and after completion of the treatment. The mean (± SD) size of the nodules of the palm before Received: 2 October 2019 treatment was 16.6 ± 5.0 mm2, which was reduced to 4.0 ± 3.8 mm2 after completion of the Accepted: 7 January 2020 treatment. This reduction was statistically significant. To identify the effective compound nuclear Available Online: 19 February 2020 magnetic resonance spectroscopy, infrared spectrophotometry, elemental analysis and liquid chromatography-mass spectroscopy of the extract were done yet conclusion could not be achieved. ISSN: 2224‐7750 (Online) 2074‐2908 (Print) DOI: 10.3329/bsmmuj.v13i1.45244 Introduction beneficial effect of the cock’s comb extract and Keywords: Arsenic; Cock‘s comb; to identify the compound that was effective in Keratosis; Palm Arsenical keratosis is not only a health problem the treatment of palmar arsenical keratosis.
  • Acid Sustained Release Tablets with Water-Insoluble Gel

    Acid Sustained Release Tablets with Water-Insoluble Gel

    '1. j Available online at www.sciencedirect.com -.._ ~. - SCll!NCl!@DIRl!CT• 1 : Ü. Kiitüphane v;;ö 1 k ILFARMACO ELSEVIER ;' No M'-ttt-15. .. II Farmaco 58 (2003) 397 - 401 www.elsevier.com/locate/farmac • . ... ····· ····· ..... acid sustained release tablets with water-insoluble gel S. Güngör *, A. Y. Özsoy, E. Cevher, A. Araman Faculty of Pharmacy, Department of Pharmaceutical Technology, /stanbul Istanbul, Turkey Received 24 April 2002; accepted 28 November 2002 Abstract Mefenamic acid (MA) has analgesic, anti-inflammatory and antipyretic properties. Available conventional dosage forms are capsules and film-coated tablets. No commercial sustained release preparation of MA exists in the market. The usual oral dose is 250 or 500 mg and reported half-life is 2 h. Sodium alginate (NaAL) is the sodium salt of alginic acid, a natura! polysaccharide extracted from marine brown algae. it has the ability to forma water-insoluble gel with a bivalent metal ions as calcium. Therefore, NaAL has been studied for preparing sustained release formulations in pharmaceutical technology. In this study, tablet formulations containing different ratios of NaAL and calcium gluconate (CaGL) were prepared by direct compression method. In vitro release studies were carried out using USP 23 basket method and release data were kinetically evaluated. According to release studies, it can be emphasized that NaAL and CaGL can be used for design of sustained release preparation of MA. © 2003 Editions scientifiques et medicales Elsevier SAS. Ali rights reserved. Mefenamic acid; Sodium alginate; Calcium g]uconate; Sustained release 1. Introduction dispersing agent and gelation agent (10]. NaAL has the ability of forming rapid viscous solutions and gels by its Mefenamic acid (MA), 2-((2,3-dimethylphenyl)ami- contacts with aqueous media.
  • Methyl Salicylate, Menthol, Camphor Cream Semprae

    Methyl Salicylate, Menthol, Camphor Cream Semprae

    FLEXILON- methyl salicylate, menthol, camphor cream Semprae Laboratories Inc Disclaimer: Most OTC drugs are not reviewed and approved by FDA, however they may be marketed if they comply with applicable regulations and policies. FDA has not evaluated whether this product complies. ---------- ACTIVE INGREDIENT Camphor 4% Menthol 7.5% Methyl Salicylate 10% PURPOSE Topical analgesic USES For the temporary relief of minor aches and pains of muscles and joints associated with: simple backache arthritis strains bruises sprains WARNINGS For external use only Do not use on wounds or damaged , broken or irritated skin with a heating pad When using this product avoid contact with eyes or mucous membranes do not bandage tightly Stop use and ask a doctor if condition worsens you have redness over the affected area symptoms persist for more than 7 days or symptoms clear up and occur within a few days excessive skin irritation occurs Keep out of reach of children If swallowed, get medical help or contact a Poison Center immediately DIRECTIONS use only as directed Adults and children 12 years of age and older: Apply to affected area not more than 3 to 4 times daily. Children under 12 years of age: consult a doctor. OTHER INFORMATION store at 20-25C (68-77F) Do not purchase if outer seal is broken INACTIVE INGREDIENTS carbomer, cetearyl alcohol, D.I. water, FD&C Blue no. 1, FD&C Yellow no.5, glucosamine sulfate, glyceryl monostearate, methyl sulfonyl methane, methylparaben, mineral oil 90, PEG-100, propylparaben, polysorbate 60, stearyl alcohol, triethanolamine
  • Dietary Supplements for Osteoarthritis Philip J

    Dietary Supplements for Osteoarthritis Philip J

    Dietary Supplements for Osteoarthritis PHILIP J. GREGORY, PharmD; MORGAN SPERRY, PharmD; and AmY FRIEdmAN WILSON, PharmD Creighton University School of Pharmacy and Health Professions, Omaha, Nebraska A large number of dietary supplements are promoted to patients with osteoarthritis and as many as one third of those patients have used a supplement to treat their condition. Glucosamine-containing supplements are among the most commonly used products for osteo- arthritis. Although the evidence is not entirely consistent, most research suggests that glucos- amine sulfate can improve symptoms of pain related to osteoarthritis, as well as slow disease progression in patients with osteoarthritis of the knee. Chondroitin sulfate also appears to reduce osteoarthritis symptoms and is often combined with glucosamine, but there is no reliable evi- dence that the combination is more effective than either agent alone. S-adenosylmethionine may reduce pain but high costs and product quality issues limit its use. Several other supplements are promoted for treating osteoarthritis, such as methylsulfonylmethane, Harpagophytum pro- cumbens (devil’s claw), Curcuma longa (turmeric), and Zingiber officinale (ginger), but there is insufficient reliable evidence regarding long-term safety or effectiveness. Am( Fam Physician. 2008;77(2):177-184. Copyright © 2008 American Academy of Family Physicians.) ietary supplements, commonly glycosaminoglycans, which are found in referred to as natural medicines, synovial fluid, ligaments, and other joint herbal medicines, or alternative structures. Exogenous glucosamine is derived medicines, account for nearly from marine exoskeletons or produced syn- D $20 billion in U.S. sales annually.1 These thetically. Exogenous glucosamine may have products have a unique regulatory status that anti-inflammatory effects and is thought to allows them to be marketed with little or no stimulate metabolism of chondrocytes.4 credible scientific research.
  • Evaluation of Glucosamine Sulfate Compared to Ibuprofen for the Treatment of Temporomandibular Joint Osteoarthritis

    Evaluation of Glucosamine Sulfate Compared to Ibuprofen for the Treatment of Temporomandibular Joint Osteoarthritis

    Evaluation of Glucosamine Sulfate Compared to Ibuprofen for the Treatment of Temporomandibular Joint Osteoarthritis: A Randomized Double Blind Controlled 3 Month Clinical Trial NORMAN M.R. THIE, NARASIMHA G. PRASAD, and PAUL W. MAJOR ABSTRACT. Objective. To compare the treatment potential of glucosamine sulfate (GS) and ibuprofen in patients diagnosed with temporomandibular joint (TMJ) osteoarthritis (OA). Methods. Forty women and 5 men received either GS (500 mg tid) or ibuprofen (400 mg tid) for 90 days in a randomized double blind study. Assessment: TMJ pain with function, pain-free, and volun- tary maximum mouth opening, Brief Pain Inventory (BPI) questionnaire and masticatory muscle tenderness were performed after a one week washout and at Day 90. Acetaminophen (500 mg) dispensed for breakthrough pain was counted every 30 days to Day 120. Results. In total, 176 adults were interviewed, 45 (26%) qualified, 39 (87%) completed the study (21 GS, 18 ibuprofen). Four discontinued due to stomach upset (3 ibuprofen, one GS), one due to dizzi- ness (GS), one due to inadequate pain control (ibuprofen). Within-group analysis revealed signifi- cant improvement compared to baseline of all variables in both treatment groups but no change in acetaminophen used. Fifteen GS (71%) and 11 ibuprofen (61%) improved, with positive clinical response taken as a 20% decrease in primary outcome (TMJ pain with function). The number of patients with positive clinical response was not statistically different between groups (p = 0.73). Between-group comparison revealed that patients taking GS had a significantly greater decrease in TMJ pain with function, effect of pain, and acetaminophen used between Day 90 and 120 compared with patients taking ibuprofen.
  • Exploitation of Marine-Derived Robust Biological Molecules to Manage Inflammatory Bowel Disease

    Exploitation of Marine-Derived Robust Biological Molecules to Manage Inflammatory Bowel Disease

    marine drugs Review Exploitation of Marine-Derived Robust Biological Molecules to Manage Inflammatory Bowel Disease Muhammad Bilal 1,* , Leonardo Vieira Nunes 2 , Marco Thúlio Saviatto Duarte 3 , Luiz Fernando Romanholo Ferreira 4,5 , Renato Nery Soriano 6 and Hafiz M. N. Iqbal 7,* 1 School of Life Science and Food Engineering, Huaiyin Institute of Technology, Huaian 223003, China 2 Department of Medicine, Federal University of Juiz de Fora, Juiz de Fora-MG 36036-900, Brazil; [email protected] 3 Department of Medicine, Federal University of Juiz de Fora, Governador Valadares-MG 35010-180, Brazil; [email protected] 4 Graduate Program in Process Engineering, Tiradentes University (UNIT), Av. Murilo Dantas, 300, Farolândia, Aracaju-Sergipe 49032-490, Brazil; [email protected] 5 Institute of Technology and Research (ITP), Tiradentes University (UNIT), Av. Murilo Dantas, 300, Farolândia, Aracaju-Sergipe 49032-490, Brazil 6 Division of Physiology and Biophysics, Department of Basic Life Sciences, Federal University of Juiz de Fora, Governador Valadares-MG 35010-180, Brazil; [email protected] 7 School of Engineering and Sciences, Tecnologico de Monterrey, Monterrey 64849, Mexico * Correspondence: [email protected] or [email protected] (M.B.); hafi[email protected] (H.M.N.I.) Abstract: Naturally occurring biological entities with extractable and tunable structural and func- tional characteristics, along with therapeutic attributes, are of supreme interest for strengthening the twenty-first-century biomedical settings. Irrespective of ongoing technological and clinical ad- Citation: Bilal, M.; Nunes, L.V.; vancement, traditional medicinal practices to address and manage inflammatory bowel disease Duarte, M.T.S.; Ferreira, L.F.R.; (IBD) are inefficient and the effect of the administered therapeutic cues is limited.